

**A Comprehensive Study Global Market Potential for Therapies of
Urinary Bladder Cancer**

Submitted By:

Shriyani Roy

IIHMR-U/02/2022-24/0440

CONTENTS

INTRODUCTION



RESEARCH METHODOLOGY



REVIEW OF LITRATURE



RESULTS AND DISCUSSION



CONCLUSION



BIBLIOGRAPHY

RESEARCH OBJECTIVES

To assess the current situation of the Global bladder cancer market and its overall projections based on each segment and estimating the growth rate.

To assess the future projections based on each segment and estimating the growth rate.

To observe the recent shift in diagnosis, treatments towards novel approaches.

To establish a competitive analysis of the dominant players in the market based on the product portfolio, growth, financials and strategies

RESEARCH METHODOLOGY

- **Research Design:** The research methodology used for the study involves mixed methods which combine qualitative and quantitative techniques. It covers a plethora of topics like data collection, data analysis, ethical issues, validity, dependability, as well as restrictions and presumptions. This mixed approach will help to understand and underline the comprehensive analysis of the market.
- **Study Plan**
- **Duration of Study: 3 Months**
- **Sample Size & Sampling Technique**
- **Sample Size:** The size of sample varied based on the number of companies targeted. The database contained a list of 800 companies along with their products to analyze the market. The companies were surveyed and thoroughly studied their published reports.
- **Sampling Technique:** Stratified Sampling- In this the market was sectionalized based on product type, treatment type, treatment channel, diagnostic tools, and regional analysis along with their growth factors.

Global Bladder Cancer Treatment Historical Market (2016-2022)

Key Takeaway

The growth of the global bladder cancer treatment has been growing due to the rising number of smokers across the globe.

CAGR (2016-2022) 4.97%

2016 12.6 USD Billion

2022 16.9 USD Billion

Global Bladder Cancer Treatment Historical
Market - 2016-2022, (USD Billion)



Market Outlook

- Cancer is among one of the leading causes of death across the globe. Smoking accounts for almost 50% of the bladder cancer causes in the United States.
- The rising number of bladder cancer cases can be attributed to the late detection of the disease among the patients.
- Rising cases of bladder cancer can also be attributed to the consumption of drinking water high levels of arsenic .

Global Bladder Cancer Treatment Market Forecast (2023-2031)

Key Takeaway


The growth of the market is likely to be propelled by the expected increase in the approval of new drugs and treatments.

CAGR (2023-2031) 4.37%

2023 17.4 USD Billion

2031 24.5 USD Billion

Global Bladder Cancer Treatment Forecast Market
– 2023-2031, (USD Billion)



Market Outlook


- The global bladder cancer treatment market growth is likely to be driven by the rising competition among the key players and the consequent rise in the clinical trial pipeline.
- The treatment market is expected to flourish further in the coming years as the cases of bladder cancer are rapidly rising due to the lack of purified drinking water.
- The prevalence of the disease is also anticipated to rise due to some birth defects in bladder or due to the long-term use of urinary catheters.

Global Bladder Cancer Treatment Market by Type (2016-2022)


**Key
Takeaway**

Based on type, the transitional bladder cancer segment has been leading the global market and held a significant share of 86.68% in 2022 and is expected to account for a share of 74.62% by 2031.

Global Bladder Cancer Treatment Historical Market (In %)




Global Bladder Cancer Treatment Market Forecast (In %)



Global Bladder Cancer Treatment Market by Type (2016-2022)


**Key
Takeaway**

Based on type, the market is likely to be dominated by the non-invasive treatments as it is more convenient for the patients and invasive procedures are mostly the last resort.




Invasive Bladder Cancer

The rising demand for non-muscle invasive treatment has been aiding the growth of this type. It accounted for a market share of 13.2% in 2022.



Transitional Bladder Cancer

The transitional bladder cancer is the most common type and accounts for 90% of the total cases. It accounted for a market share of 77.9% in 2022.



Squamous Cell Bladder Cancer


The squamous cell bladder cancer is the least common type of bladder cancer in the market, which accounted for a market share of 5.1% in 2022.

Global Bladder Cancer Treatment Market by Diagnosis Method (2016-2031)


Key Takeaway

Based on diagnosis, the cystoscopy bladder cancer segment has been leading the global market and held a significant share of 45.5% in 2022 and is expected to account for a share of 44.2% by 2031.

Global Bladder Cancer Treatment Historical Market (In %)



Global Bladder Cancer Treatment Market Forecast (In %)




Global Bladder Cancer Treatment Market by Treatment Method (2016-2031)

Key Takeaway

Based on treatment method, the transitional bladder cancer segment has been leading the global market and held a significant share of 86.68% in 2022 and is expected to account for a share of 74.62% by 2031.


Global Bladder Cancer Treatment Historical Market (In %)

2022



Global Bladder Cancer Treatment Market Forecast (In %)

2031



Global Bladder Cancer Treatment Market by Treatment Channel (2016-2031)

Key Takeaway

The global bladder cancer treatment market, based on treatment channel, can be divided into public and private sectors. Private sector has been leading the market with a share of 56.6% in 2022 and is likely to account for a significant share of 60.8% by 2031.

Global Bladder Cancer Treatment Historical Market (In %)

2022





Global Bladder Cancer Treatment Market Forecast (In %)

2031



Global Bladder Cancer Market - Regional Comparison (2022)


Market Share -2022 (In %)




North America – 5.54		Europe – 6.16		Asia Pacific – 2.84		LATAM -1.05		Middle East and Africa - 1.32	
	USA – 5.10		Germany – 1.53		China- 0.54		Brazil- 0.36		Saudi Arabia-0.15
	Canada – 0.44		France – 0.97		Japan- 1.05		Mexico – 0.24		South Africa- 0.11
			UK – 0.85		India- 0.37		Argentina- 0.09		Nigeria- 0.17
			Italy- 1.06		ASEAN- 0.20		Rest of LATAM 0.36		UAE- 0.08

Global Bladder Cancer Treatment Historical Market by Region (2016-2031)


North America




Latin America




Asia Pacific



Europe




Middle East and Africa




Global Bladder Cancer Treatment Market – Clinical Trials Analysis


Clinical Trials Distribution by Year




Clinical Trials Distribution by Trial Status




Clinical Trials Distribution by Study Type




Clinical Trials Distribution by Trial Phases



Top Active Sponsors




Top Countries running Clinical Trials




Global Bladder Cancer Treatment Market – Patent Landscape


Patent Publications by Year




Patent Distribution by Patent Status




Patent Distribution by Documentation Type




Patent Expiration Age




Most Active Industry Players





Top Jurisdictions for Patent



Global Bladder Cancer Treatment Market Funding and Grant Analysis



Global Bladder Cancer Treatment Market Partnership Analysis



Global Bladder Cancer Treatment Market – Patent CPC Landscape

CPC Code	01	02	06	07	08	10	12	16	23	33	40	61	82
A- Human Necessities													
B- Performing Operations; Transporting													
C- Chemistry; Metallurgy													
G- Physics													
H- Electricity													
Y- General Tagging of New Technological Development													

A23 - foods or foodstuffs; treatment thereof, not covered by other classes

A61 - medical or veterinary science; hygiene

B01 - physical or chemical processes or apparatus in general

B33 - additive manufacturing technology

B82 - nanotechnology

C07 - organic chemistry

C08 - organic macromolecular compounds; their preparation or chemical working-up; compositions based thereon

C12 - biochemistry; beer; spirits; wine; vinegar; microbiology; enzymology; mutation or genetic engineering

C40 - combinatorial technology

G01 - measuring; testing

G06 - computing; calculating or counting

G16 - information and communication technology [ict] specially adapted for specific application fields

H01 - electric elements

Y02 - technologies or applications for mitigation or adaptation against climate change

Y10 - technical subjects covered by former uspc

Cost of Treatment

Key Takeaway


Due to the risk of recurrence, many people who have been diagnosed with bladder cancer are worried about the cost of the disease and its treatment. The average cost of bladder cancer is estimated to be between USD 60,000 to 70,000.

- The estimated national expenditures for bladder cancer care was USD 8.3 billion in 2015 and reached about USD 9.4 in 2020.
- 60% of the costs, were due to surveillance and treatment of recurrences.
- 30 % of the costs were due to complications from bladder cancer.
- The most expensive stage III patients for bladder cancer have the highest lifetime expenses.
- The majority of the expenses for all phases are driven by hospitalizations.
- The majority of these hospitalizations did not incur expenses for cystectomy.

Factors influence the total financial impact of bladder cancer

- Type of treatment required
- Length of the patient's treatment
- How far the patient must travel while receiving treatment
- Patient's health insurance coverage

US Bladder Cancer Expenditure



CONCLUSION

- On performing the study, it was concluded that this market is a ever increasing market with a need for more treatment methods and advancements taking place by various companies are making this market a competitive one.
- Due to the ever-increasing number of cases in bladder cancer market attributed to various factors, it has been shown that the market has been on a steady rise from the year 2016 where it was USD Billion 12.6 and grew at a CAGR of 4.97% to USD 16.9 Billion in 2022. The market showed a rise in 2023 catering to USD 17.4 Billion and the projections suggest that it will reach USD 24.5 Billion in 2031 with a CAGR of 4.37%.
- The other reasons are the constant launch of new medicines and approvals by the regulatory bodies. This growth in the market is creating a lucrative option for the companies to invest in bladder cancer domain.

BIBLIOGRAPHY

- Van Hoogstraten L.M.C, Vrieling A, van der Heijden, A.G. et al. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. *Nat Rev Clin Oncol* 20, 287–304 (2023). <https://doi.org/10.1038/s41571-023-00744-3>
- Parkin D. M. (2008). The global burden of urinary bladder cancer. *Scandinavian Journal of Urology and Nephrology*, 42(sup218), 12–20. <https://doi.org/10.1080/03008880802285032>
- Zhang Y Rungay H, Li M, Yu H, Pan H, Ni J. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. *J Glob Health*. 2023 Sep 15;13:04109. doi: 10.7189/jogh.13.04109. PMID: 37712386; PMCID: PMC10502766.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71:209-49. 10.3322/caac.21660